Tango Therapeutics (TNGX) AI Stock Analysis

• Market Cap: $1.75B
• Dividend Yield: N/A
• Average Volume (3M): 2.77M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.37
• Revenue Growth: 53.28%
• EPS Growth: 21.77%
• Country: US
• Employees: 155
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): 0.14
• Shares Outstanding: 134,677,100
• 10 Day Avg. Volume: 3,593,086
• 30 Day Avg. Volume: 2,767,882
• PEG Ratio: -0.25
• Price to Book (P/B): 1.69
• Price to Sales (P/S): 8.02
• P/FCF Ratio: -2.55
• Enterprise Value/Market Cap: 0.52
• Enterprise Value/Revenue: 13.66
• Enterprise Value/Gross Profit: 13.91
• Enterprise Value/Ebitda: -8.74
• 1Y Price Target: $13.71
• Price Target Upside: 5.38% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): -1.25
• Revenue Forecast (FY): $8.42M

• Rating: 53 Neutral
• Price Target: $13.00 ▼(-0.08% Downside)

The score is held back primarily by weak financial performance (persistent losses and negative cash flows). Technicals are a meaningful offset with a strong uptrend, though overbought signals add near-term risk. Valuation is pressured by negative earnings, while corporate events are moderately positive due to strengthened leadership/governance and added funding despite dilution.

Positive Factors

Precision oncology platform

Tango’s genetic and computational focus on synthetic lethality targets creates a durable competitive edge by enabling tumor-specific therapies and clearer biomarker-driven patient selection. This platform can generate multiple programs and attract partners, supporting sustained R&D productivity and licensing opportunities.

Strengthened leadership and governance

The CEO transition plus the founder’s move to Executive Chair preserves strategic continuity while adding new operational leadership. Combined with an added independent director with finance and biopharma experience, this governance upgrade should improve execution of registrational plans and investor communication over the next several quarters.

Improved near-term funding runway

The sizable registered offering and reported cash balance extend runway into 2028, materially reducing immediate financing pressure. That funding allows Tango to execute pivotal and combination studies, derisk programs toward value inflection points, and avoid urgent capital raises that could disrupt development timelines.

Negative Factors

Negative operating and free cash flow

Persistent negative operating and free cash flow forces recurring capital raises, creating dilution risk and limiting strategic flexibility. Until products generate sales or large milestone receipts occur, ongoing cash burn constrains the company’s ability to scale trials, absorb delays, or invest in broader commercial capabilities.

Ongoing net losses and weak profitability

Despite strong gross margins, Tango remains unprofitable at the EBIT and net levels. Sustained losses mean shareholder value hinges on successful clinical outcomes or partnerships; absent regulatory approvals and product revenue, profitability remains a structural risk for several years.

Revenue dependent on collaborations and milestones

As a clinical-stage biotech, Tango’s revenues are lumpy and milestone-driven, lacking recurring product sales. This makes cash flow timing unpredictable, increases reliance on external funding, and can cap upside from successful drugs if partnerships allocate a large share of future commercial economics to collaborators.

Tango Therapeutics Business Overview & Revenue Model

Company Description

Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company also develops Ubiquitin-specific protease 1, an inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. Tango Therapeutics, Inc. has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. The company was founded in 2017 and is based in Cambridge, Massachusetts.

How the Company Makes Money

Tango Therapeutics generates revenue primarily through partnerships and collaborations with pharmaceutical companies, which may involve licensing agreements for its proprietary drug candidates. Additionally, the company may receive milestone payments as its products progress through various stages of development and regulatory approval. Revenue may also come from grants and funding from research institutions or government bodies aimed at supporting its research initiatives. The company’s ability to monetize its intellectual property and the success of its therapeutic candidates in clinical trials are significant factors contributing to its earnings.

Tango Therapeutics Financial Statement Overview

Summary

Tango Therapeutics demonstrates strong revenue growth and efficient cost management, as seen in its high gross profit margin. However, the company faces significant profitability challenges with persistent losses and negative cash flows. While leverage is low, the negative return on equity and cash flow issues suggest financial instability. Continued focus on improving profitability and cash flow is essential for future stability.

Income Statement

Tango Therapeutics shows a strong gross profit margin, indicating efficient cost management. However, the company struggles with negative net profit and EBIT margins, reflecting ongoing losses. Revenue growth is notable, especially in the TTM period, but profitability remains a challenge.

Balance Sheet

The company's debt-to-equity ratio is relatively low, suggesting manageable leverage. However, the negative return on equity indicates that the company is not generating profit from its equity base. The equity ratio is stable, showing a solid equity position relative to total assets.

Cash Flow

Tango Therapeutics faces negative operating and free cash flows, which are concerning for liquidity. The free cash flow to net income ratio is slightly above 1, indicating that cash flow is closely aligned with net income losses. The negative growth in free cash flow highlights cash flow challenges.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	66.50M	42.07M	36.53M	24.86M	37.04M	7.66M
Gross Profit	65.32M	42.07M	36.53M	24.86M	37.04M	6.03M
EBITDA	-103.96M	-143.10M	-111.76M	-109.46M	-57.29M	-50.35M
Net Income	-100.52M	-130.30M	-101.74M	-108.18M	-58.23M	-51.97M
Balance Sheet
Total Assets	210.14M	316.49M	402.57M	436.47M	500.15M	207.25M
Cash, Cash Equivalents and Short-Term Investments	152.81M	257.92M	336.88M	366.13M	485.25M	190.32M
Total Debt	34.76M	36.49M	38.92M	41.13M	1.50M	7.88M
Total Liabilities	50.10M	116.97M	149.46M	186.99M	155.41M	168.65M
Stockholders Equity	160.03M	199.52M	253.11M	249.48M	344.75M	38.60M
Cash Flow
Free Cash Flow	-146.76M	-132.25M	-119.51M	-116.77M	-61.36M	68.97M
Operating Cash Flow	-145.81M	-131.50M	-117.98M	-109.08M	-59.53M	70.07M
Investing Cash Flow	146.91M	86.13M	41.43M	26.40M	-183.43M	-145.47M
Financing Cash Flow	4.09M	47.66M	82.41M	1.61M	357.32M	80.88M

Tango Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 13.01
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TNGX, the sentiment is Positive. The current price of 13.01 is above the 20-day moving average (MA) of 9.90, above the 50-day MA of 9.40, and above the 200-day MA of 6.28, indicating a bullish trend. The MACD of 0.82 indicates Negative momentum. The RSI at 67.86 is Neutral, neither overbought nor oversold. The STOCH value of 89.73 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for TNGX.

Tango Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
IMTX	56 Neutral	$1.32B	-8.99	-29.01%	―	-27.61%	-69.49%
SPRY	54 Neutral	$1.05B	-13.12	-45.92%	―	5459.66%	-59.70%
TNGX	53 Neutral	$1.75B	-14.20	-51.65%	―	53.28%	21.77%
UPB	52 Neutral	$1.68B	-13.57	-40.80%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
PRME	50 Neutral	$718.43M	-2.70	-112.34%	―	647.13%	26.79%
ORKA	41 Neutral	$1.62B	-13.82	-23.05%	―	―	63.85%

Tango Therapeutics Corporate Events

Tango Therapeutics appoints new CEO amid leadership transition

On January 8, 2026, Tango Therapeutics announced a planned leadership transition in which founding chief executive Barbara Weber, M.D., retired from the CEO role and became Executive Chair for 2026, moving to non-executive chair in 2027, while remaining involved in strategic priorities and clinical execution; the company emphasized that her departure from the CEO position was not due to any disagreement over operations or policies. Effective the same day, board member and oncology veteran Malte Peters, M.D., was appointed President and Chief Executive Officer with a compensation and equity package designed to align him with long-term shareholder value, as Tango renewed its 2026 clinical guidance for key milestones, including registrational and combination studies of vopimetostat and early-stage data from TNG456, underscoring management’s focus on advancing its precision oncology pipeline into pivotal development and potential commercialization.

The most recent analyst rating on (TNGX) stock is a Hold with a $12.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.

Tango Therapeutics Adds Independent Director to Strengthen Governance

On January 2, 2026, Tango Therapeutics, Inc. expanded its Board of Directors from seven to eight members and appointed Sung H. Lee as an independent Class I director, with a term running until the 2028 annual meeting of stockholders. Lee, a seasoned finance executive with more than two decades of leadership experience at biopharmaceutical and technology firms including Cytokinetics, Vir Biotechnology, MorphoSys, Sangamo Therapeutics and Gilead Sciences, received a standard non-employee director compensation package comprising stock options for 60,000 shares, 10,000 restricted stock units vesting over three years, and a $40,000 annual cash retainer, and is expected to enter into the company’s customary director indemnification agreement. Tango’s leadership highlighted that Lee’s background in corporate strategy, investor relations and finance is expected to support the company as it advances its lead cancer program, vopimetostat, into registrational studies and continues to evolve its organization for late-stage clinical development, underscoring a strategic strengthening of its governance and financial oversight as it approaches critical milestones in its pipeline.

The most recent analyst rating on (TNGX) stock is a Hold with a $10.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.

Tango Therapeutics Enters New Sales Agreement with Leerink

On November 21, 2025, Tango Therapeutics entered into a Sales Agreement with Leerink Partners LLC to sell up to $100 million of its common stock through an at-the-market offering. This move follows the termination of a previous sales agreement with Jefferies LLC, effective the same day, indicating a shift in the company’s strategy for raising capital.

The most recent analyst rating on (TNGX) stock is a Buy with a $14.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.

Tango Therapeutics Announces Major Stock Offering

On October 23, 2025, Tango Therapeutics announced a registered direct offering of 21,023,337 shares of common stock and pre-funded warrants to purchase an additional 3,226,458 shares, expected to raise approximately $197 million. The proceeds will be used to advance the company’s pipeline and support general corporate purposes, with the offering anticipated to close on October 24, 2025. Additionally, Tango entered into a private placement agreement with an accredited investor for 1,732,101 shares, expected to generate $15 million. These financial moves are intended to fund operations and capital expenditures into 2028, strengthening Tango’s position in the biotechnology industry.

The most recent analyst rating on (TNGX) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.

Tango Therapeutics Announces Preliminary Financial Results

On October 23, 2025, Tango Therapeutics announced preliminary unaudited financial results, estimating $152.8 million in cash and marketable securities as of September 30, 2025. The company also provided a clinical update on its ongoing Phase 1/2 trial of vopimetostat, highlighting its potential as a best-in-class treatment for MTAP-deleted solid tumors, with plans for a pivotal study in second-line pancreatic cancer to begin in 2026.

The most recent analyst rating on (TNGX) stock is a Hold with a $9.00 price target. To see the full list of analyst forecasts on Tango Therapeutics stock, see the TNGX Stock Forecast page.